Immuno-oncology

Results from the phase 3 RATIONALE 302 trial showed tislelizumab-jsgr prolonged survival compared to chemotherapy in patients who received prior systemic treatment.

Less manufacturing time could be the difference between a patient receiving this life-saving therapy vs not.

The immune checkpoint inhibitor increased inflammation within the tumor, which may be linked to better response to nivolumab treatment.

The candidate has already demonstrated anti-tumor activity in chemotherapy-naïve patients.

Nearly 75% of patients who had an initial complete response with mosunetuzumab maintained that complete response after 3 years.

New CAR T development method infuses immune T cells from healthy people into patients to improve outcomes.

The CAR T-cell therapy improved relative overall survival by more than a third compared to standard of care.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Pembrolizumab (Keytruda) gains its sixth approval in non–small cell lung cancer (NSCLC), with the latest indication in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a monotherapy for the post-surgical adjuvant treatment of patients with resectable NSCLC.

Investigators reported that enfortumab vedotin-ejfv (Padcev; Astella Pharma Inc, Seagen Inc) in combination with pembrolizumab (Keytruda; Merck & Co Inc) met the dual primary endpoints of overall survival and progression-free survival in patients with previously untreated locally advanced or metastatic urothelial cancer.

Most patients had improved clinical response within 90 days of receiving the dendritic cell vaccine and ASCT.

Nivolumab has also demonstrated efficacy in immunotherapy-based combinations for the treatment of certain types of melanoma and bladder cancers.

Axicabtagene ciloleucel achieved a complete metabolic response of 71% at 3 months versus 12% expected with standard of care among transplant ineligible patients with relapsed/refractory large B-cell lymphoma.

Microbubble cell separation can make next generation treatments, such as CAR T-cell therapy, more accessible.

The use of base editing to generate universal, off-the-shelf CAR T cells is a promising approach for relapsed leukemia, with potential implications for the future of gene therapy.

Precision medicine in pharmacy has the potential to revolutionize patient care by optimizing drug selection, dosing, and monitoring.

Protection of T cells from tumor-induced suppression suggests potential for enhancing efficacy of therapies, with plans to initiate a phase 1/2 clinical trial in patients with advanced breast cancer.

Opportunities for an additional specialization in molecular pathology may be helpful to train professionals in the real-time interpretation of gene therapy test results.

New data have resulted in updated guidelines for neoadjuvant cemiplimab.

Niraparib and abiraterone acetate (Akeega; Janssen Pharmaceutical Companies of Johnson & Johnson) is the first-and-only dual action tablet that combines a PARP inhibitor with abiraterone acetate administered with prednisone.

Precision therapies, although effective in earlier stages, may not work later.

Microgravity provides researchers with a unique environment for studying how cells behave differently than they do on Earth.

Talquetamab-tgvs (Talvey) is a first-in-class bispecific antibody that binds to GPRC5D and CD3 to induce T cell-mediated killing of GPRC5D-expressing multiple myeloma cells.

Early safety studies of NK-cell infusion have demonstrated the potential of NK-cell infusion, showing it may be the next revolution in cancer treatment.

Pembrolizumab is already indicated to treat patients with unresectable or metastatic melanoma, along with stage 2B-3 melanoma after resection in adults and pediatric patients.

FRα expression is limited on normal cells, but upregulated in ovarian cancer cells.

With approximately 2 years of additional follow-up, lenvatinib plus pembrolizumab maintained robust effectiveness for nearly every patient.

Nivolumab-based combinations have shown significant survival benefits across several tumor types, including melanoma and advanced renal cell carcinoma.

Memory killer cells have been shown to respond to immunotherapy, which is normally administered as a complement to other cancer treatments.

Treatment with lisocabtagene maraleucel led to strong and durable response rates with little serious adverse effects in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.